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Experience Remains Key*Jeffrey B. Geske, MD, Bernard J. Gersh, MB, CHB, DPHILI n this issue of JACC: Cardiovascular Interventions,Steggerda et al. (1) present a single-centerexperience comparing alcohol septal ablation
(ASA) and septal myectomy for the treatment of
symptomatic patients with hypertrophic obstructive
cardiomyopathy. They present results of 102 myec-
tomy and 161 ASA patients studied over a mean of
9.1 and 5.1 years, respectively. They note higher
periprocedural complication rates with myectomy,
driven primarily by a high rate of repeat thoracot-
omy (most commonly for hemothorax and residual
gradient). There were no differences between the
procedures in annual mortality (including sudden
cardiac death), symptomatic status, or, somewhat
surprisingly, permanent pacemaker implantation.SEE PAGE 1227Myectomy is a well-established, effective surgical
technique with decades of experience in its use
(2). Since its introduction in 1995 (3), use of ASA has
increased precipitously given a percutaneous app-
roach, such that there are estimates of >5,000 pro-
cedures performed over the course of less than a
decade, more than the number of septal myectomies
performed in the past half century (4). Olivotto et al. (5)
previously outlined the impracticality of a theoretical
randomized, controlled trial comparing ASA and my-
ectomy, which would necessitate screening of 34,000
patients for enrollment and randomization of 600
patients in each arm. Therefore, existing published
data comparing the 2 techniques is limited to regis-
tries and meta-analyses. There remains substantial*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
From the Division of Cardiovascular Diseases, Mayo Clinic College of
Medicine, Rochester, Minnesota. Both authors have reported that they
have no relationships relevant to the contents of this paper to disclose.controversy regarding choice of procedure (4,6).
Current American College of Cardiology Foundation/
American Heart Association guidelines recommend
septal myectomy at experienced centers as the ﬁrst
consideration for septal reduction therapy (Class IIa,
Level of Evidence: B) and ASA as an alternative in
selected patients with contraindication to myectomy
or who favor ASA over myectomy following informed
discussion (Class IIb, Level of Evidence: B) (6).
The present study highlights the paramount im-
portance of procedural experience. Myectomy was
performed at a rate of 3.5 operations/year (102/29
years), whereas ASA was pursued at a rate >16 pro-
cedures/year (161/10 years). Put in this context, the
post-myectomy perioperative mortality rate of 2%,
the high rate of perioperative complications (28%)
including permanent pacemaker implantation in 9%,
and lengthy post-myectomy hospital stay (mean 9
days) may indeed relate to operative experience as
opposed to inherent procedural limitations. Current
guidelines stress the need for extensive procedural
experience for both myectomy and ASA, deﬁned as
>20 procedures per individual operator or a program
with >50 procedures, mortality rates <1%, complica-
tion rates <3%, and documented success at symptom
relief (7). In contrast to the current series, we per-
formed 232 myectomies at our institution in 2013
alone. We previously reported our operative results,
with a myectomy mortality rate <1%, a pacemaker
implantation rate of 2.4%, and hospital length of stay
a median of 6 days, comparable to the ASA experience
reported here (8). Similar results have been reported
at the Cleveland Clinic (9) and other high-volume
myectomy centers (10). Although the anatomic site
of septal myectomy frequently results in post-
operative left bundle branch block (11), in the absence
of preexisting right bundle branch block, it is difﬁcult
to explain the high rate of permanent pacemaker
implantation in the present study.
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1236Subjectively assessed symptomatic status post-
procedurally was similar between the myectomy and
ASA groups, consistent with known meta-analysis
data (12), although interestingly objective quantiﬁ-
cation of cardiopulmonary exercise capacity has
shown more improvement with myectomy com-
pared with ASA in previous evaluation (13). Whether
this relates to less long-term gradient reduction
with ASA (a ﬁnding again demonstrated herein) is
unknown.
Arrhythmogenic risk post-ablation remains an area
of uncertainty. On the basis of MRI (14) and necropsy
studies (15), it is clear that ASA is associated with
scarring not seen in myectomy. As the authors
appropriately cite, there have been reports of higher
rates of implantable cardiac deﬁbrillator discharge
after ASA (16). In the current evaluation, increased
arrhythmogenesis was not seen, a ﬁnding echoed in
other recent studies (17). However, given the differ-
ences in follow-up duration, further longitudinal
assessment is warranted.
Where do we go from here? Myectomy has a proven
track record of success, yet it is clear that the percu-
taneous appeal of ASA remains attractive to both
physicians and patients. In experienced centers of
excellence, ASA may be a reasonable alternativeto myectomy in selected patients. A comparison of
age- and sex-matched patients undergoing ASA and
myectomy at our center revealed no signiﬁcant dif-
ference in survival free of death or need for additional
septal reduction therapy; however, there was greater
symptom relief in young patients with myectomy
and more pacemaker implantation with ASA (18).
Assessment of procedural success and risk must be
individualized on the basis of both the patient and
institutional experience. The present investigation
has signiﬁcant potential for skewing of results on the
basis of the discrepant rates of myectomy and ASA. A
thorough investigation of adverse procedural out-
comes and septal reduction therapy comparative
effectiveness remains of immense clinical value, a
point emphasized in the guidelines (7). However, it
remains clear that procedural success is closely linked
to institutional experience, and septal reduction
therapies should be limited to referral centers of
excellence.
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